Moderna : 2024 outlook confirmed, gradual ramp-up of RSV vaccine
>Q3 better than expected thanks to earlier Covid vaccination season - Despite a high-quality Q3, the stock remained under pressure at the end of the week with a slower than expected ramp-up in the group’s RSV vaccine, the commercial launch of its Covid/seasonal flu vaccine that is expected more for the 2026 season and obviously the question marks around the future US government’s positioning on vaccination programmes. Overall, sales came in well ahead of expectations ...Moderna is creating a new generation of medicines based on messenger RNA to improve the lives of patients. The company uses its platform to identify and develop new mRNA medicines. When the company identifies a combination of platform technologies or programs across mRNA technologies, delivery technologies, and manufacturing processes that can enable shared product features across multiple potential mRNA medicines, it groups those programs as a modality. The company has created six modalities including prohylactic vaccines; cancer vaccines; intratumoral immuno-oncology; localized regenerative therapeuctics; systemic secreted therapeutics; and systemic intracellular therapeutics.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.